Skip to main content
Premium Trial:

Request an Annual Quote

Anagnostics Inks Italian Sales Deal for KRAS CDx

NEW YORK (GenomeWeb News) – Austrian firm Anagnostics Bioanalysis today announced a deal granting Italian company Cell.ENG the exclusive right to sell Anagnostics' KRAS mutation test in Italy.

Terms of the deal were not disclosed.

The Anagnostics KRAS Test is for detecting mutations in the KRAS gene. Such mutations have been shown to limit the efficacy of cancer therapeutics that block the epidermal growth factor receptor. The test is based on a technology called hybcell, which Anagnostics called "a unique further development of the microarray technology."

"[T]he microarray is integrated into a rotating cylinder filled with the [patient] sample," it said, adding the technology enables the measurement of "many test parameters" simultaneously.

Markus Jacquemar, CEO of Anagnostics, said in a statement, "Up until now, the real time polymerase chain reaction was considered to be state-of-the-art for companion diagnostics in the area of mutation analysis. Our technology now not only enables faster and unambiguous results, but also higher sensitivity and simpler operation."

The company is working with Diatech Pharmacogenetics on developing combined tests for the KRAS, BRAF, and EGFR genes to be sold across Europe. Anagnostics has secured funding from Technet Equity NO Technologiebeteiligungs-Invest, it said.

The company, founded in 2006, develops systems and tests for research and clinical multiplex diagnostics.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.